Abstract
Novel 2-[3-(4-bromo-2-fluorobenzyl)-4-oxo-3,4-dihydro-1-phthalazinyl]acetic acid hydrazones were synthesized from phthalic anhydride by a six step synthesis and evaluated for in vitro, in vivo activities against eight mycobacterial species and Mycobacterium tuberculosis (MTB) isocitrate lyase (ICL) enzyme inhibition studies. Among twenty six compounds N1-[(4-nitrophenyl)methylene]-2-[3-(4-bromo-2-fluorobenzyl)-4-oxo-1,2,3,4-tetrahydro-1-phthalazinyl]ethanohydrazide (7j) was found to be the most active compound in-vitro with MICs of 0.18 and < 0.09 μM against log-phase cultures of MTB and multi-drug resistant MTB respectively. Compound 7j inhibited all the eight mycobacterial species with MIC ranging from < 0.09-12.25 μM and was not toxic to Vero cell lines till 122.5 μM. Seven compounds were tested against starved culture of MTB and they inhibited with MICs ranging from 2.88-8.91 μM. Some compounds showed 45- 61% inhibition against MTB ICL enzyme at 10 μM. In the in vivo animal model 7j decreased the bacterial load in lung and spleen tissues with 1.87 and 3.03-log10 protections respectively at 25 mg/kg body weight dose.
Keywords: Phthalazine, Antimycobacterial, Mycobacterium tuberculosis, Isocitrate lyase
Medicinal Chemistry
Title: Novel Pthalazinyl Derivatives: Synthesis, Antimycobacterial Activities, and Inhibition of Mycobacterium Tuberculosis Isocitrate Lyase Enzyme
Volume: 5 Issue: 5
Author(s): D. Sriram, P. Yogeeswari, P. Senthilkumar, S. Dewakar, N. Rohit, B. Debjani, Pritesh Bhat, B. Veugopal, V. V.S. Pavan and H. M. Thimmappa
Affiliation:
Keywords: Phthalazine, Antimycobacterial, Mycobacterium tuberculosis, Isocitrate lyase
Abstract: Novel 2-[3-(4-bromo-2-fluorobenzyl)-4-oxo-3,4-dihydro-1-phthalazinyl]acetic acid hydrazones were synthesized from phthalic anhydride by a six step synthesis and evaluated for in vitro, in vivo activities against eight mycobacterial species and Mycobacterium tuberculosis (MTB) isocitrate lyase (ICL) enzyme inhibition studies. Among twenty six compounds N1-[(4-nitrophenyl)methylene]-2-[3-(4-bromo-2-fluorobenzyl)-4-oxo-1,2,3,4-tetrahydro-1-phthalazinyl]ethanohydrazide (7j) was found to be the most active compound in-vitro with MICs of 0.18 and < 0.09 μM against log-phase cultures of MTB and multi-drug resistant MTB respectively. Compound 7j inhibited all the eight mycobacterial species with MIC ranging from < 0.09-12.25 μM and was not toxic to Vero cell lines till 122.5 μM. Seven compounds were tested against starved culture of MTB and they inhibited with MICs ranging from 2.88-8.91 μM. Some compounds showed 45- 61% inhibition against MTB ICL enzyme at 10 μM. In the in vivo animal model 7j decreased the bacterial load in lung and spleen tissues with 1.87 and 3.03-log10 protections respectively at 25 mg/kg body weight dose.
Export Options
About this article
Cite this article as:
Sriram D., Yogeeswari P., Senthilkumar P., Dewakar S., Rohit N., Debjani B., Bhat Pritesh, Veugopal B., Pavan V.S. V. and Thimmappa M. H., Novel Pthalazinyl Derivatives: Synthesis, Antimycobacterial Activities, and Inhibition of Mycobacterium Tuberculosis Isocitrate Lyase Enzyme, Medicinal Chemistry 2009; 5 (5) . https://dx.doi.org/10.2174/157340609789117886
DOI https://dx.doi.org/10.2174/157340609789117886 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
Call for Papers in Thematic Issues
Recent Advances in the Medicinal Chemistry of Cancer
Scope of the Thematic Issue: Correlation between structure and function is one of the important aspects of the success of anti-cancer compounds associated with their structure-activity interactions, physiology, biochemical, molecular, and genetic processes. Overcoming these obstacles is key to obtaining further insights into developments in rational drug design, bioorganic chemistry, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Advances in the Development of Adenovirus- and Poxvirus- Vectored Tuberculosis Vaccines
Current Gene Therapy T-Lymphocytes: A Target for Stimulatory and Inhibitory Effects of Zinc Ions
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Developments in Protein and Cell-Targeted Aptamer Selection and Applications
Current Medicinal Chemistry Exploring and Prioritization of Mobile-Based Self-Management Strategies for HIV Care
Infectious Disorders - Drug Targets Strategic Paradigm Shifts in the Antimicrobial Drug Discovery Process of the 21st Century
Infectious Disorders - Drug Targets Life Threatening and Fatal Contrast Media Reactions: Pathomechanisms, Diagnosis, Prevention and Drug Management
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Natural Products as Leads for Tuberculosis Drug Development
Current Topics in Medicinal Chemistry Design, Synthesis and In Vitro Anti-Mycobacterial Activity of Chromene Fused Cytosine and Uracil Analogues
Anti-Infective Agents Cytokine Status of Serum in Ovarian Cancer Patients with Different Tumor Neoadjuvant Chemotherapy Response
Anti-Cancer Agents in Medicinal Chemistry Itraconazole vs Fluconazole as a Primary Prophylaxis for Fungal Infections in HIV-Infected Patients in Thailand
Current HIV Research Randomized Clinical Trials in Children - Ethical and Methodological Issues
Current Pharmaceutical Design Monoclonal Antibodies, Bispecific Antibodies and Antibody-Drug Conjugates in Oncohematology
Recent Patents on Anti-Cancer Drug Discovery Biologic Therapy in Inflammatory Eye Conditions (Ophtalmology): Safety Profile
Current Drug Safety Targeting Bacterial Metalloenzymes: A New Strategy for the Development of Anti-Infective Agents
Anti-Infective Agents in Medicinal Chemistry 4-Mer Hyaluronan Oligosaccharides Stimulate Inflammation Response in Synovial Fibroblasts in Part via TAK-1 and in Part via p38-MAPK
Current Medicinal Chemistry Editorial from Guest Editor (Thematic Issue: Tuberculosis: Recent Advances in Our Understanding and Management)
Current Respiratory Medicine Reviews Resources and Tools for Investigating Biomolecular Networks in Mammals
Current Pharmaceutical Design Systemic Inflammation, Infection, ApoE Alleles, and Alzheimer Disease: A Position Paper
Current Alzheimer Research Synthesis and Evaluation of New Thiazole Derivatives as Potential Antimicrobial Agents
Letters in Drug Design & Discovery Central Nervous System Vasculitis: Still More Questions than Answers
Current Neuropharmacology